However, whether the clinical benefits of SGLT2 inhibitors in heart failure extend to all subpopulations, including those at the highest end of the ejection fraction spectrum28 and those already treated with other therapies commonly used in heart failure29, has not been clarified. The gene discussed is SLC5A2; the disease is heart failure.